ArticleJournal of ovarian research2025
Association between plasma extracellular vesicles LncRNAs and metabolic syndrome in polycystic ovary syndrome.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThis case-control study aimed to investigate the relationship between plasma EVs LncRNAs, specifically Xist, MALAT1, and NEAT1, and MetS in PCOS patients, to identify a novel biomarker for early MetS diagnosis in these patients.
methodsThe levels of Xist, MALAT1, and NEAT1 in PCOS patients with and without MetS were quantified using qRT-PCR and then compared. Generalized linear regression and trend regression analyses were utilized to examine the association between three LncRNAs and MetS. ROC curve, DCA, AIC assessment, and importance ranking were applied to assess the clinical value of the three LncRNAs for MetS in PCOS patients.
resultsThe study included 220 newly diagnosed PCOS patients, with 82 (37.273%) having MetS. The expression levels of Xist, MALAT1, and NEAT1 were lower in PCOS patients with MetS compared to those without MetS (all P < 0.001). Further, significant independent associations between the three LncRNAs and MetS occurrence were found (all P < 0.05), with a negative relationship. Among three LncRNAs, MALAT1 had the superior performance (AUC = 0.801) in discriminative the occurrence of MetS in PCOS patients. In addition, MALAT1 also showed the highest importance for the risk of MetS.
conclusionThe low expressions of Xist, MALAT1, and NEAT1 were associated with the high risk of MetS in PCOS patients, with MALAT1 potentially serving as a preferred molecular marker for discriminative MetS in PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.